Perspectives on cost and value in cancer care

JAMA Oncology

Volumn 2, Issue 1, 2016, Pages 19-21

  Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; NEOPLASMS; ONCOLOGY; QUALITY ADJUSTED LIFE YEAR; SOCIOECONOMICS; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE PATTERNS, PHYSICIANS'; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME; VALUE OF LIFE;

EID: 84973503043     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4191     Document Type: Editorial

References (17)

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) vs IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015; 33(suppl;abstr LBA1).
2. ASP prices source. Redbook online: 1st Quarter 2015. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html?redirect=/. Accessed May 21, 2015.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
4. Avorn J. The $2.6 billion pill: methodologic and policy considerations. N Engl J Med. 2015;372(20):1877-1879.
5. Bach PB. Could high drug prices be bad for innovation? http://www.forbes.com/sites/matthewherper/2014/10/23/could-high-drug-prices-be-bad-for-innovation/. Accessed May 21, 2015.
6. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539-540 doi:10.1001/jamaoncol.2015.0373.
7. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139-162. doi:10.1257/jep.29.1.139.
8. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532. doi:10.1056/NEJMoa1503093.
9. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028. doi:10.1056/NEJMoa1501824.
10. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520. doi:10.1056/NEJMoa1500596.
11. Definition of "unsustainable." Dictionary.com's 21st Century Lexicon. http://dictionary.reference.com/browse/unsustainable?s=t. Accessed May 21, 2015.
12. Young RA, DeVoe JE. Who will have health insurance in the future? an updated projection. Ann Fam Med. 2012;10(2):156-162.
13. Schrag D, Dueck AC, Naughton MJ, et al Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405. J Clin Oncol. 2015;33(suppl; abstr 6504).
14. Schnipper L, Davidson N, Wollins D, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options [published online June 22, 2015]. JCO. doi:10.1200/JCO.2015.61.6706.
15. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547-1573.
16. Statement of Mission and Goals. Memorial Sloan Kettering Cancer Center web site. https://one.mskcc.org/sites/pub/ha/Policies/HA-1001.pdf. Accessed May 20, 2015.
17. Geisel TS. The Lorax. New York, NY: Random House; 1971.